Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference
Vaxart OTCMKTS: VXRT Chief Executive Officer Steve Lo outlined the company's oral vaccine platform, its government-funded COVID-19 study and development opportunities in norovirus and influenza during an H.C. Wainwright conference presentation.
Vaxart Q2 Earnings Call Highlights
Vaxart OTCMKTS: VXRT said it has reported positive 12-month safety data from the 400-participant Sentinel cohort of its Phase II-B COVID-19 vaccine trial and remains on track to disclose top-line data from the larger, approximately 5,000-participant main cohort in the first half of 2027.
Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript
Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript
Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now
Vaxart OTCMKTS: VXRT held its 2026 Annual Meeting of Stockholders, where investors re-elected the company's full slate of directors, ratified its auditor and rejected the company's non-binding advisory proposal on executive compensation.
Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript
Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript
Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript
Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript
Vaxart, Inc. (VXRT) Q4 2025 Earnings Call Transcript
Vaxart, Inc. (VXRT) Q4 2025 Earnings Call Transcript
Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript
Vaxart, Inc. (OTC:VXRT) Shareholder/Analyst Call November 18, 2025 4:30 PM EST Company Participants Steven Lo - President, CEO & Director Jeroen Grasman - CFO, Principal Accounting Officer & Principal Financial Officer Edward Berg - Senior VP & General Counsel Sean Tucker - Senior VP & Chief Scientific Officer James Cummings - Chief Medical Officer Conference Call Participants David Carey - Finn Partners, Inc. Presentation Operator Greetings, and welcome to the Vaxart Stockholder Fireside Chat Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript
Vaxart, Inc. (OTC:VXRT) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Edward Berg - Senior VP & General Counsel Steven Lo - President, CEO & Director James Cummings - Chief Medical Officer Sean Tucker - Senior VP & Chief Scientific Officer Jeroen Grasman - CFO, Principal Accounting Officer & Principal Financial Officer Conference Call Participants Cheng Li - Oppenheimer & Co. Inc., Research Division Nabeel Nissar - Jefferies LLC, Research Division Presentation Operator Greetings, and welcome to the Vaxart Business Update and Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript
Vaxart, Inc. (OTC:VXRT) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Edward B. Berg - Senior VP & General Counsel James F.
VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates
VAXART, INC. (VXRT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09.
Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript
Vaxart, Inc. (NASDAQ:VXRT ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Ed Berg - SVP and General Counsel Steven Lo - CEO James Cummings - CMO Sean Tucker - Founder and CSO Phillip Lee - CFO Conference Call Participants Cheng Li - Oppenheimer Mayank Mamtani - B. Riley Securities Liang Cheng - Jefferies Operator Greetings.
